{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:12:46Z","timestamp":1771902766361,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["No 801481"],"award-info":[{"award-number":["No 801481"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF19OC0058603"],"award-info":[{"award-number":["NNF19OC0058603"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R231-A13820"],"award-info":[{"award-number":["R231-A13820"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R231-A13832"],"award-info":[{"award-number":["R231-A13832"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Hovedstadens Forskningsfond","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Simon Fougner Hartmanns family foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant mesothelioma (MM) is a highly aggressive cancer with limited therapeutic options. We have previously shown that the endocytic collagen receptor, uPARAP, is upregulated in certain cancers and can be therapeutically targeted. Public RNA expression data display uPARAP overexpression in MM. Thus, to evaluate its potential use in diagnostics and therapy, we quantified uPARAP expression by immunohistochemical H-score in formalin-fixed paraffin-embedded bioptic\/surgical human tissue samples and tissue microarrays. We detected pronounced upregulation of uPARAP in the three main MM subtypes compared to non-malignant reactive mesothelial proliferations, with higher expression in sarcomatoid and biphasic than in epithelioid MM. The upregulation appeared to be independent of patients\u2019 asbestos exposure and unaffected after chemotherapy. Using immunoblotting, we demonstrated high expression of uPARAP in MM cell lines and no expression in a non-malignant mesothelial cell line. Moreover, we showed the specific internalization of an anti-uPARAP monoclonal antibody by the MM cell lines using flow cytometry-based assays and confocal microscopy. Finally, we demonstrated the sensitivity of these cells towards sub-nanomolar concentrations of an antibody-drug conjugate formed with the uPARAP-directed antibody and a potent cytotoxin that led to efficient, uPARAP-specific eradication of the MM cells. Further studies on patient cohorts and functional preclinical models will fully reveal whether uPARAP could be exploited in diagnostics and therapeutic targeting of MM.<\/jats:p>","DOI":"10.3390\/ijms222111452","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:06:16Z","timestamp":1635113176000},"page":"11452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8384-5209","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00c7ak\u0131lkaya","sequence":"first","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke Raagaard","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-2307","authenticated-orcid":false,"given":"Henrik Jessen","family":"J\u00fcrgensen","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-0426","authenticated-orcid":false,"given":"Oliver","family":"Krigslund","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-3567","authenticated-orcid":false,"given":"Henrik","family":"G\u00e5rdsvoll","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffer F.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Adcendo ApS, c\/o Copenhagen Bio Science Park (COBIS), 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-3535","authenticated-orcid":false,"given":"Eric","family":"Santoni-Rugiu","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"},{"name":"Department of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-3922","authenticated-orcid":false,"given":"Niels","family":"Behrendt","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1232","authenticated-orcid":false,"given":"Lars H.","family":"Engelholm","sequence":"additional","affiliation":[{"name":"Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cakiroglu, E., and Senturk, S. (2020). Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176342"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel Therapies for Malignant Pleural Mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.33433","article-title":"Malignant Mesothelioma: Advances in Immune Checkpoint Inhibitor and Mesothelin-Targeted Therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"B057","DOI":"10.1158\/1535-7163.TARG-19-B057","article-title":"Abstract B057: BMS-986148, an Anti-Mesothelin Antibody-Drug Conjugate (ADC), Alone or in Combination with Nivolumab Demonstrates Clinical Activity in Patients with Select Advanced Solid Tumors","volume":"18","author":"Clarke","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I Study of DMOT4039A, an Antibody\u2013Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chia, P.-L., Parakh, S., Tsao, M.-S., Pham, N.-A., Gan, H.K., Cao, D., Burvenich, I.J.G., Rigopoulos, A., Reilly, E.B., and John, T. (2020). Targeting and Efficacy of Novel MAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100289"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"TPS3652","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3652","article-title":"SGN228-001: A Phase I Open-Label Dose-Escalation, and Expansion Study of SGN-CD228A in Select Advanced Solid Tumors","volume":"38","author":"Patnaik","year":"2020","journal-title":"JCO"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody\u2013Drug Conjugates in Solid Tumors: A Look into Novel Targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26996","DOI":"10.1074\/jbc.M110.208033","article-title":"The Non-Phagocytic Route of Collagen Uptake: A Distinct Degradation Pathway","volume":"286","author":"Madsen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1083\/jcb.200211091","article-title":"UPARAP\/Endo180 Is Essential for Cellular Uptake of Collagen and Promotes Fibroblast Collagen Adhesion","volume":"160","author":"Engelholm","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3892\/ijo.2015.3120","article-title":"The Collagen Receptor UPARAP\/Endo180 in Tissue Degradation and Cancer (Review)","volume":"47","author":"Melander","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2741\/3365","article-title":"The Collagen Receptor UPARAP\/Endo180","volume":"14","author":"Engelholm","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"44605","DOI":"10.18632\/oncotarget.17883","article-title":"The Collagen Receptor UPARAP\/Endo180 as a Novel Target for Antibody-Drug Conjugate Mediated Treatment of Mesenchymal and Leukemic Cancers","volume":"8","author":"Nielsen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_19","unstructured":"(2021, August 22). The Cancer Genome Atlas Program\u2014National Cancer Institute, Available online: https:\/\/www.cancer.gov\/about-nci\/organization\/ccg\/research\/structural-genomics\/tcga."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_21","unstructured":"(2021, June 15). GEPIA. Available online: http:\/\/gepia.cancer-pku.cn\/detail.php?gene=MRC2."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1369\/jhc.6A7133.2006","article-title":"Increased Expression of the Collagen Internalization Receptor UPARAP\/Endo180 in the Stroma of Head and Neck Cancer","volume":"55","author":"Sulek","year":"2007","journal-title":"J. Histochem. Cytochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27037","DOI":"10.1074\/jbc.M701088200","article-title":"Extracellular Collagenases and the Endocytic Receptor, Urokinase Plasminogen Activator Receptor-Associated Protein\/Endo180, Cooperate in Fibroblast-Mediated Collagen Degradation","volume":"282","author":"Madsen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.10227","article-title":"Urokinase Receptor-Associated Protein (UPARAP) Is Expressed in Connection with Malignant as Well as Benign Lesions of the Human Breast and Occurs in Specific Populations of Stromal Cells","volume":"98","author":"Nielsen","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","volume":"11","author":"Churg","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ajcp\/aqab054","article-title":"Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma","volume":"156","author":"Schulte","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-1759(98)00189-6","article-title":"Different Mechanisms Are Involved in the Antibody Mediated Inhibition of Ligand Binding to the Urokinase Receptor: A Study Based on Biosensor Technology","volume":"222","author":"List","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127640","DOI":"10.1016\/j.bmcl.2020.127640","article-title":"Evaluation of PNU-159682 Antibody Drug Conjugates (ADCs)","volume":"30","author":"Holte","year":"2020","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/path.4661","article-title":"Targeting a Novel Bone Degradation Pathway in Primary Bone Cancer by Inactivation of the Collagen Receptor UPARAP\/Endo180","volume":"238","author":"Engelholm","year":"2016","journal-title":"J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2373997515600403","DOI":"10.1177\/2373997515600403","article-title":"Molecular-Targeted Therapy for Malignant Mesothelioma","volume":"2","author":"Tada","year":"2015","journal-title":"PLEURA"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody\u2013Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jin, Y., Schladetsch, M.A., Huang, X., Balunas, M.J., and Wiemer, A.J. (2021). Stepping Forward in Antibody-Drug Conjugate Development. Pharmacol. Ther., 107917.","DOI":"10.1016\/j.pharmthera.2021.107917"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Affatato, R., Mendogni, P., Del Gobbo, A., Ferrero, S., Ricci, F., Broggini, M., and Rosso, L. (2020). Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. Cancers, 12.","DOI":"10.3390\/cancers12123846"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19138","DOI":"10.1038\/s41598-020-75995-6","article-title":"Tumor Cell MT1-MMP Is Dispensable for Osteosarcoma Tumor Growth, Bone Degradation and Lung Metastasis","volume":"10","author":"Ingvarsen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"32506","DOI":"10.1074\/jbc.M801924200","article-title":"Antibody-Mediated Targeting of the Urokinase-Type Plasminogen Activator Proteolytic Function Neutralizes Fibrinolysis In Vivo","volume":"283","author":"Lund","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear Grade and Necrosis Predict Prognosis in Malignant Epithelioid Pleural Mesothelioma: A Multi-Institutional Study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jcp.48.9.876","article-title":"A \u201cQuickscore\u201d Method for Immunohistochemical Semiquantitation: Validation for Oestrogen Receptor in Breast Carcinomas","volume":"48","author":"Detre","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","article-title":"Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival","volume":"7","author":"Zimling","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-013-2329-0","article-title":"Changes in Epidermal Growth Factor Receptor Expression during Chemotherapy in Non-Small Cell Lung Cancer","volume":"73","author":"Jakobsen","year":"2014","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:08Z","timestamp":1760167328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":41,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111452"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111452","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]}}}